COMMUNIQUÉS West-GlobeNewswire

CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy
23/03/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 23, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that it has completed initial signature mapping of its asset [...]
Onconetix, Inc. Announces 1-for-5 Reverse Stock Split
23/03/2026
CINCINNATI, Ohio, March 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of [...]
Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering
23/03/2026
CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Laigo Bio completes final close of oversubscribed seed financing of €17 million co-led by Biovance Capital and Kurma Partners to advance oncology and auto-immunity programs
23/03/2026
Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m. Funds will be used to further develop Laigo’s SureTACs™ targeted protein [...]
Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive Officer
23/03/2026
BASEL, Switzerland, March 23, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with precision biologics, announces today the appointment of Thaminda [...]
Philips convenes the Annual General Meeting of Shareholders 2026
23/03/2026
March 23, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published [...]
Persica Pharmaceuticals Appoints Dr Edward Littler as Executive Chairman and David Watson as Chief Executive Officer
23/03/2026
New senior executives bring significant biopharma experience as Persica moves to next phase of its development London, UK, 23 March 2026 - Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology [...]
Groundbreaking Danish research project launches to cure Parkinson’s disease
23/03/2026
A new research project aims to develop the world’s first therapy to eliminate and prevent the spread of a toxic brain protein that drives Parkinson’s disease. Innovation Fund Denmark has invested DKK 26,689,872million [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
23/03/2026
COPENHAGEN, Denmark, March 23, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up [...]
Amphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs
23/03/2026
Cambridge, UK, 23 rd March 2026 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces three upcoming [...]
Philips proposes new appointment and re-appointments to its Supervisory Board and CEO re-appointment
23/03/2026
March 23, 2026 John DeFord proposed as new member of the Supervisory Board. Paul Stoffels, Herna Verhagen and Sanjay Poonen proposed for re-appointment as members of the Supervisory Board. Marc Harrison will step down [...]
Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 – World’s Premier Cancer Research Forum
23/03/2026
Accepted Abstracts Highlight Advances in AI-Driven Oncology Pipeline VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO0), a biopharmaceutical company [...]
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
23/03/2026
Allschwil, Switzerland, March 23, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
CoaguSense Announces Agreement to Acquire DOASENSE DOAC Testing Business, Expanding Leadership in Anticoagulation Monitoring
23/03/2026
FREMONT, Calif., March 22, 2026 (GLOBE NEWSWIRE) -- CoaguSense, Inc., a leading developer of point-of-care coagulation monitoring systems and a subsidiary of i-SENS, Inc. (KOSDAQ: 099190), today announced it has entered [...]
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
23/03/2026
New Rhapsido ® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented Long-term Cosentyx ® data build on extensive body of evidence supporting [...]
ONWARD Medical Schedules Webcast to Report Full-Year 2025 Financial Results and Provide Business Update
23/03/2026
EINDHOVEN, the Netherlands, March 23, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and [...]
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
23/03/2026
Webcast to be held Monday, March 23rd at 8:00 a.m. ET SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, [...]
INB.bio Launches 2026 Growth Strategy With New Market Entries Across Africa, MENA and Southeast Asia
23/03/2026
The direct advertiser and wellness infrastructure company targets five new countries as global wellness demand accelerates in emerging markets BERLIN, March 22, 2026 (GLOBE NEWSWIRE) -- Global demand for wellness [...]
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
23/03/2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III [...]

Pages